Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy.
Schnegg-Kaufmann AS. et al, (2022), Blood
CNL and aCML should be considered as single entity based on molecular profiles and outcomes.
Carreño-Tarragona G. et al, (2022), Blood Adv
Single-cell methods in myeloproliferative neoplasms - old questions, new technologies.
O'Sullivan JM. et al, (2022), Blood
MPN-238 Single-Cell RNA Profiling of Myelofibrosis Patients Reveals Pelabresib-Induced Decrease of Megakaryocytic Progenitors and Normalization of CD4+ T Cells in Peripheral Blood.
Zavidij O. et al, (2022), Clin Lymphoma Myeloma Leuk, 22 Suppl 2, S331 - S332
Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis.
Harrison CN. et al, (2022), Future Oncol
CD34+CD19-CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies.
Bueno C. et al, (2022), Blood, 140, 38 - 44
In utero origin of myelofibrosis presenting in adult monozygotic twins.
Sousos N. et al, (2022), Nat Med, 28, 1207 - 1211
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia.
Mascarenhas J. et al, (2022), Blood, 139, 2931 - 2941
Exploratory Analysis: Potential of pelabresib (CPI-0610), a bromodomain and extra-terminal domain inhibitor, as suggested by analysis of improvements in bone marrow histology and function in patients with myelofibrosis-preliminary data
Harrison C. et al, (2022), BRITISH JOURNAL OF HAEMATOLOGY, 197, 27 - 28
Longitudinal and Individual Symptom Analyses of Momelotinib and Ruxolitinib-Treated Myelofibrosis Patients from SIMPLIFY-1
Mesa R. et al, (2022), BRITISH JOURNAL OF HAEMATOLOGY, 197, 79 - 80
Pelabresib (CPI-0610) monotherapy in patients with myelofibrosis-update of clinical and translational data from the ongoing MANIFEST trial
Curto-Garcia N. et al, (2022), BRITISH JOURNAL OF HAEMATOLOGY, 197, 75 - 76
A blood atlas of COVID-19 defines hallmarks of disease severity and specificity.
COvid-19 Multi-omics Blood ATlas (COMBAT) Consortium. Electronic address: julian.knight@well.ox.ac.uk None. and COvid-19 Multi-omics Blood ATlas (COMBAT) Consortium None., (2022), Cell, 185, 916 - 938.e58
A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study.
Mead AJ. et al, (2022), Ther Adv Hematol, 13
Defining disease modification in myelofibrosis in the era of targeted therapy
Pemmaraju N. et al, (2022), Cancer
Single cell genotyping of matched bone marrow and peripheral blood cells in treatment naive and AZA-treated MDS and CMML
Schnegg-Kaufmann A. et al, (2022)
Ezh2 is essential for the generation of functional yolk sac derived erythro-myeloid progenitors.
Neo WH. et al, (2021), Nat Commun, 12
A human fetal liver-derived infant MLL-AF4 acute lymphoblastic leukemia model reveals a distinct fetal gene expression program.
Rice S. et al, (2021), Nat Commun, 12